The US Food & Drug Administration will have one year to outline a new “Platform Technologies” pathway for sponsors hoping to streamline development of products that rely on a common backbone (like a vector for gene therapies) to treat different diseases under the year-end spending bill expected to be enacted in the coming days.
The “Platform Technologies” pathway is included in the PREVENT Pandemics Act, which is in turn incorporated in the “Consolidated...





